Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.

Iwaki H, Blauwendraat C, Leonard HL, Kim JJ, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Hutten SJ, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Gibbs JR; International Parkinson's Disease Genomics Consortium, Chitrala KN, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Andreassen O, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA.

Mov Disord. 2019 Sep 10. doi: 10.1002/mds.27845. [Epub ahead of print]

PMID:
31505070
2.

Continuous EEG Monitoring Predicts a Clinically Meaningful Recovery Among Adult Inpatients.

Selioutski O, Roberts D, Hamilton R, Ghosh H, Nickels J, Konig Toro F, Kruppenbacher M, Auinger P, Kaplan PW, Birbeck GL.

J Clin Neurophysiol. 2019 Sep;36(5):358-364. doi: 10.1097/WNP.0000000000000594.

PMID:
31491786
3.

Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts.

Iwaki H, Blauwendraat C, Leonard HL, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Hutten SJ, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA.

Neurol Genet. 2019 Jul 9;5(4):e348. doi: 10.1212/NXG.0000000000000348. eCollection 2019 Aug. Erratum in: Neurol Genet. 2019 Aug 15;5(4):e354.

4.

Patient Views on Telemedicine for Parkinson Disease.

Spear KL, Auinger P, Simone R, Dorsey ER, Francis J.

J Parkinsons Dis. 2019;9(2):401-404. doi: 10.3233/JPD-181557.

PMID:
31127732
5.

Environmental exposure to lead: old myths never die - Authors' reply.

Lanphear BP, Hornung RW, Auinger P, Allen R.

Lancet Public Health. 2018 Aug;3(8):e363. doi: 10.1016/S2468-2667(18)30128-2. No abstract available.

6.

Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease.

Fischer DL, Auinger P, Goudreau JL, Paumier KL, Cole-Strauss A, Kemp CJ, Lipton JW, Sortwell CE.

Parkinsonism Relat Disord. 2018 Aug;53:70-75. doi: 10.1016/j.parkreldis.2018.05.003. Epub 2018 May 9.

PMID:
29759928
7.

Low-level lead exposure and mortality in US adults: a population-based cohort study.

Lanphear BP, Rauch S, Auinger P, Allen RW, Hornung RW.

Lancet Public Health. 2018 Apr;3(4):e177-e184. doi: 10.1016/S2468-2667(18)30025-2. Epub 2018 Mar 12.

8.

Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease.

Christine CW, Auinger P, Joslin A, Yelpaala Y, Green R; Parkinson Study Group-DATATOP Investigators.

Mov Disord. 2018 May;33(5):762-770. doi: 10.1002/mds.27301. Epub 2018 Mar 6.

PMID:
29508904
9.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators.

Neurology. 2017 Dec 12;89(24):2495-2502. doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15.

10.

Analysis of Participant Withdrawal in Huntington Disease Clinical Trials.

Banno H, Andrzejewski KL, McDermott MP, Murphy A, Majumder M, de Blieck EA, Auinger P, Cudkowicz ME, Atassi N.

J Huntingtons Dis. 2017;6(4):371. doi: 10.3233/JHD-179002. No abstract available.

PMID:
28922164
11.

Virtual visits for Parkinson disease: A multicenter noncontrolled cohort.

Korn RE, Wagle Shukla A, Katz M, Keenan HT, Goldenthal S, Auinger P, Zhu W, Dodge M, Rizer K, Achey MA, Byrd E, Barbano R, Richard I, Andrzejewski KL, Schwarz HB, Dorsey ER, Biglan KM, Kang G, Kanchana S, Rodriguez R, Tanner CM, Galifianakis NB.

Neurol Clin Pract. 2017 Aug;7(4):283-295. doi: 10.1212/CPJ.0000000000000371.

12.

Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.

McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M.

J Huntingtons Dis. 2017;6(3):189-199. doi: 10.3233/JHD-170241.

PMID:
28826192
13.

Low-Level Prenatal Toxin Exposures and Breastfeeding Duration: A Prospective Cohort Study.

Rosen-Carole CB, Auinger P, Howard CR, Brownell EA, Lanphear BP.

Matern Child Health J. 2017 Dec;21(12):2245-2255. doi: 10.1007/s10995-017-2346-4.

14.

Analysis of Participant Withdrawal in Huntington Disease Clinical Trials.

Banno H, Andrzejewski KL, McDermott MP, Murphy A, Majumder M, de Blieck EA, Auinger P, Cudkowicz ME, Atassi N.

J Huntingtons Dis. 2017;6(2):149-156. doi: 10.3233/JHD-170246. Erratum in: J Huntingtons Dis. 2017;6(4):371.

15.

Metabolomic biomarkers as strong correlates of Parkinson disease progression.

LeWitt PA, Li J, Lu M, Guo L, Auinger P; Parkinson Study Group–DATATOP Investigators.

Neurology. 2017 Feb 28;88(9):862-869. doi: 10.1212/WNL.0000000000003663. Epub 2017 Feb 8.

16.

The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12.

Wall M, Kupersmith MJ, Thurtell MJ, Moss HE, Moss EA, Auinger P; NORDIC Idiopathic Intracranial Hypertension Study Group.

Am J Ophthalmol. 2017 Apr;176:102-107. doi: 10.1016/j.ajo.2017.01.004. Epub 2017 Jan 17.

17.

Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.

Majbour NK, Vaikath NN, Eusebi P, Chiasserini D, Ardah M, Varghese S, Haque ME, Tokuda T, Auinger P, Calabresi P, Parnetti L, El-Agnaf OM.

Mov Disord. 2016 Oct;31(10):1535-1542. doi: 10.1002/mds.26754.

PMID:
27548849
18.

Association of Bisphenol A exposure and Attention-Deficit/Hyperactivity Disorder in a national sample of U.S. children.

Tewar S, Auinger P, Braun JM, Lanphear B, Yolton K, Epstein JN, Ehrlich S, Froehlich TE.

Environ Res. 2016 Oct;150:112-118. doi: 10.1016/j.envres.2016.05.040. Epub 2016 Jun 6.

PMID:
27281688
19.

Etonogestrel Implants in Adolescents: Experience, Satisfaction, and Continuation.

Obijuru L, Bumpus S, Auinger P, Baldwin CD.

J Adolesc Health. 2016 Mar;58(3):284-9. doi: 10.1016/j.jadohealth.2015.10.254.

PMID:
26903428
20.

Association of pyrethroid pesticide exposure with attention-deficit/hyperactivity disorder in a nationally representative sample of U.S. children.

Wagner-Schuman M, Richardson JR, Auinger P, Braun JM, Lanphear BP, Epstein JN, Yolton K, Froehlich TE.

Environ Health. 2015 May 28;14:44. doi: 10.1186/s12940-015-0030-y.

21.

Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity.

Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Wang Y, Ginghina C, Liu C, Cain KC, Auinger P, Kang UJ, Jensen PH, Shi M, Zhang J.

Acta Neuropathol Commun. 2015 Jan 31;3:7. doi: 10.1186/s40478-015-0185-3.

22.

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.

Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P; Parkinson Study Group DATATOP Investigators, Zhang J.

Parkinsonism Relat Disord. 2015 Mar;21(3):271-6. doi: 10.1016/j.parkreldis.2014.12.027. Epub 2015 Jan 5.

23.

Association of attention-deficit/hyperactivity disorder and conduct disorder with early tobacco and alcohol use.

Brinkman WB, Epstein JN, Auinger P, Tamm L, Froehlich TE.

Drug Alcohol Depend. 2015 Feb 1;147:183-9. doi: 10.1016/j.drugalcdep.2014.11.018. Epub 2014 Dec 2.

24.

Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part II: correlations and relationship to clinical features.

OCT Sub-Study Committee for NORDIC Idiopathic Intracranial Hypertension Study Group, Auinger P, Durbin M, Feldon S, Garvin M, Kardon R, Keltner J, Kupersmith MJ, Sibony P, Plumb K, Wang JK, Werner JS.

Invest Ophthalmol Vis Sci. 2014 Nov 4;55(12):8173-9. doi: 10.1167/iovs.14-14961.

25.

Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part I: quality control, comparisons, and variability.

OCT Sub-Study Committee for NORDIC Idiopathic Intracranial Hypertension Study Group, Auinger P, Durbin M, Feldon S, Garvin M, Kardon R, Keltner J, Kupersmith M, Sibony P, Plumb K, Wang JK, Werner JS.

Invest Ophthalmol Vis Sci. 2014 Nov 4;55(12):8180-8. doi: 10.1167/iovs.14-14960. Erratum in: Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6909.

26.

Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.

Moonen AJ, Wijers A, Leentjens AF, Christine CW, Factor SA, Juncos J, Lyness JM, Marsh L, Panisset M, Pfeiffer R, Rottenberg D, Serrano Ramos C, Shulman L, Singer C, Slevin J, McDonald W, Auinger P, Richard IH.

Parkinsonism Relat Disord. 2014 Jun;20(6):644-6. doi: 10.1016/j.parkreldis.2014.02.025. Epub 2014 Mar 18.

PMID:
24679737
27.

Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J; Parkinson Study Group DATATOP Investigators.

Am J Pathol. 2014 Apr;184(4):966-975. doi: 10.1016/j.ajpath.2013.12.007. Epub 2014 Mar 11.

28.

Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.

Constantinescu R, Elm J, Auinger P, Sharma S, Augustine EF, Khadim L, Kieburtz K; NET-PD Investigators.

Mov Disord. 2014 Feb;29(2):263-5. doi: 10.1002/mds.25734. Epub 2013 Dec 3.

29.

Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease.

Zhang J, Mattison HA, Liu C, Ginghina C, Auinger P, McDermott MP, Stewart T, Kang UJ; Parkinson Study Group DATATOP Investigators, Cain KC, Shi M.

Acta Neuropathol. 2013 Nov;126(5):671-82. doi: 10.1007/s00401-013-1121-x. Epub 2013 May 4.

30.

The relationships between sugar-sweetened beverage intake and cardiometabolic markers in young children.

Kosova EC, Auinger P, Bremer AA.

J Acad Nutr Diet. 2013 Feb;113(2):219-27. doi: 10.1016/j.jand.2012.10.020.

31.

Electron microscopy of endocytic pathways.

Ranftler C, Auinger P, Meisslitzer-Ruppitsch C, Ellinger A, Neumüller J, Pavelka M.

Methods Mol Biol. 2013;931:437-47. doi: 10.1007/978-1-62703-056-4_22.

PMID:
23027016
32.

Screening, brief intervention, and referral to treatment (SBIRT) for alcohol and other drug use among adolescents: evaluation of a pediatric residency curriculum.

Ryan SA, Martel S, Pantalon M, Martino S, Tetrault J, Thung SF, Bernstein SL, Auinger P, Green ML, Fiellin DA, O'Connor PG, D'Onofrio G.

Subst Abus. 2012;33(3):251-60. doi: 10.1080/08897077.2011.640182.

PMID:
22738002
33.

Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.

Paumier KL, Siderowf AD, Auinger P, Oakes D, Madhavan L, Espay AJ, Revilla FJ, Collier TJ; Parkinson Study Group Genetics Epidemiology Working Group.

Mov Disord. 2012 Jun;27(7):880-7. doi: 10.1002/mds.24978. Epub 2012 May 3.

PMID:
22555881
34.

Activity enhances dopaminergic long-duration response in Parkinson disease.

Kang UJ, Auinger P; Parkinson Study Group ELLDOPA Investigators.

Neurology. 2012 Apr 10;78(15):1146-9. doi: 10.1212/WNL.0b013e31824f8056. Epub 2012 Mar 28.

35.

Racial trends in sugar-sweetened beverage consumption among US adolescents: 1988-2004.

Bremer AA, Byrd RS, Auinger P.

Int J Adolesc Med Health. 2011;23(3):279-86.

PMID:
22191196
36.

Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study.

Dorsey R, Biglan K, Eberly S, Auinger P, Brocht A, Umeh CC, Oakes D, Clarence-Smith K, Marshall F, Shoulson I, Frank S.

PLoS Curr. 2011 Nov 13;3:RRN1283. doi: 10.1371/currents.RRN1283.

37.

Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.

Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H; Parkinson Study Group DATATOP Investigators.

PLoS One. 2011;6(8):e22854. doi: 10.1371/journal.pone.0022854. Epub 2011 Aug 11.

38.

CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.

LeWitt P, Schultz L, Auinger P, Lu M; Parkinson Study Group DATATOP Investigators.

Brain Res. 2011 Aug 23;1408:88-97. doi: 10.1016/j.brainres.2011.06.057. Epub 2011 Jul 1.

39.

Determination of minimal clinically important change in early and advanced Parkinson's disease.

Hauser RA, Auinger P; Parkinson Study Group.

Mov Disord. 2011 Apr;26(5):813-8. doi: 10.1002/mds.23638. Epub 2011 Mar 24.

PMID:
21437987
40.

Combination feeding of breast milk and formula: evidence for shorter breast-feeding duration from the National Health and Nutrition Examination Survey.

Holmes AV, Auinger P, Howard CR.

J Pediatr. 2011 Aug;159(2):186-91. doi: 10.1016/j.jpeds.2011.02.006. Epub 2011 Mar 22.

PMID:
21429512
41.

High prevalence of hypovitaminosis D status in patients with early Parkinson disease.

Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V; Parkinson Study Group DATATOP Investigators.

Arch Neurol. 2011 Mar;68(3):314-9. doi: 10.1001/archneurol.2011.30.

PMID:
21403017
42.

US adolescent nutrition, exercise, and screen time baseline levels prior to national recommendations.

Foltz JL, Cook SR, Szilagyi PG, Auinger P, Stewart PA, Bucher S, Baldwin CD.

Clin Pediatr (Phila). 2011 May;50(5):424-33. doi: 10.1177/0009922810393499. Epub 2011 Jan 31.

PMID:
21282256
44.

Sugar-Sweetened Beverage Intake Trends in US Adolescents and Their Association with Insulin Resistance-Related Parameters.

Bremer AA, Auinger P, Byrd RS.

J Nutr Metab. 2010;2010. pii: 196476. doi: 10.1155/2010/196476. Epub 2009 Sep 6.

45.

Contribution of tobacco smoke exposure to learning disabilities.

Anderko L, Braun J, Auinger P.

J Obstet Gynecol Neonatal Nurs. 2010 Jan-Feb;39(1):111-117. doi: 10.1111/j.1552-6909.2009.01093.x.

PMID:
20409109
46.

Estimated burden of rotavirus-associated diarrhea in ambulatory settings in the United States.

Flores AR, Szilagyi PG, Auinger P, Fisher SG.

Pediatrics. 2010 Feb;125(2):e191-8. doi: 10.1542/peds.2008-1262. Epub 2010 Jan 25.

PMID:
20100749
47.

The relationship between uric acid levels and Huntington's disease progression.

Auinger P, Kieburtz K, McDermott MP.

Mov Disord. 2010 Jan 30;25(2):224-8. doi: 10.1002/mds.22907.

48.

Association of tobacco and lead exposures with attention-deficit/hyperactivity disorder.

Froehlich TE, Lanphear BP, Auinger P, Hornung R, Epstein JN, Braun J, Kahn RS.

Pediatrics. 2009 Dec;124(6):e1054-63. doi: 10.1542/peds.2009-0738. Epub 2009 Nov 23.

49.

Levodopa response in early Parkinson's disease.

Hauser RA, Auinger P, Oakes D; Parkinson Study Group.

Mov Disord. 2009 Dec 15;24(16):2328-36. doi: 10.1002/mds.22759.

PMID:
19908302
50.

Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.

Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG, Auinger P, Chou KL, Growdon JC; Parkinson Study Group DATATOP Investigators.

Neurology. 2009 Nov 3;73(18):1469-77. doi: 10.1212/WNL.0b013e3181bf992f.

Supplemental Content

Loading ...
Support Center